A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Clinical trial NCT02352948 · COMPLETED

Trial details

NCT number: NCT02352948
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Non - Small Cell Lung Cancer NSCLC

Start date: 2015-01-13
Primary completion: 2018-02-09
Enrollment: 597

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.